abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

このページは 日本語 では利用できません。English で表示されています

企業の回答

2006年11月1日

著者:
Novartis

Response by Novartis to statement by Physicians for Social Justice (Nigeria)

Dr. Igboekwu raises many points and we would like to comment on two specific assumptions he makes. The first is that generic competition makes medicines more affordable to patients in the developing world, and the second is that generics are the panacea to enabling access to medicines.

タイムライン